Preinvasive  ||| S:0 E:12 ||| JJ
lesions  ||| S:12 E:20 ||| NNS
in  ||| S:20 E:23 ||| IN
gynaecology  ||| S:23 E:35 ||| NNS
-  ||| S:35 E:37 ||| :
uterine  ||| S:37 E:45 ||| FW
cervix  ||| S:45 E:52 ||| FW
Preinvasive  ||| S:52 E:64 ||| FW
lesion  ||| S:64 E:71 ||| FW
of  ||| S:71 E:74 ||| IN
the  ||| S:74 E:78 ||| DT
uterine  ||| S:78 E:86 ||| JJ
cervix  ||| S:86 E:93 ||| NN
can  ||| S:93 E:97 ||| MD
give  ||| S:97 E:102 ||| VB
rise  ||| S:102 E:107 ||| NN
to  ||| S:107 E:110 ||| TO
cervical  ||| S:110 E:119 ||| VB
cancer ||| S:119 E:125 ||| NN
.  ||| S:125 E:127 ||| .
High-risk  ||| S:127 E:137 ||| JJ
human  ||| S:137 E:143 ||| JJ
papillomaviruses  ||| S:143 E:160 ||| NN
with  ||| S:160 E:165 ||| IN
high  ||| S:165 E:170 ||| JJ
oncogenic  ||| S:170 E:180 ||| JJ
potential  ||| S:180 E:190 ||| NN
are  ||| S:190 E:194 ||| VBP
considered  ||| S:194 E:205 ||| VBN
to  ||| S:205 E:208 ||| TO
be  ||| S:208 E:211 ||| VB
the  ||| S:211 E:215 ||| DT
main  ||| S:215 E:220 ||| JJ
etiopathological  ||| S:220 E:237 ||| JJ
factors  ||| S:237 E:245 ||| NNS
with  ||| S:245 E:250 ||| IN
interaction  ||| S:250 E:262 ||| NN
of  ||| S:262 E:265 ||| IN
other  ||| S:265 E:271 ||| JJ
risk  ||| S:271 E:276 ||| NN
factors  ||| S:276 E:284 ||| NNS
( ||| S:284 E:285 ||| -LRB-
recurrent  ||| S:285 E:295 ||| JJ
inflammation  ||| S:295 E:308 ||| NN
of  ||| S:308 E:311 ||| IN
the  ||| S:311 E:315 ||| DT
cervix ||| S:315 E:321 ||| NN
,  ||| S:321 E:323 ||| ,
injury  ||| S:323 E:330 ||| NN
of  ||| S:330 E:333 ||| IN
the  ||| S:333 E:337 ||| DT
cervix ||| S:337 E:343 ||| NN
,  ||| S:343 E:345 ||| ,
immunosuppressive  ||| S:345 E:363 ||| JJ
conditions ||| S:363 E:373 ||| NNS
,  ||| S:373 E:375 ||| ,
sexual  ||| S:375 E:382 ||| JJ
promiscuity ||| S:382 E:393 ||| NN
,  ||| S:393 E:395 ||| ,
etc. ||| S:395 E:399 ||| FW
) ||| S:399 E:400 ||| -RRB-
.  ||| S:400 E:402 ||| .
Early  ||| S:402 E:408 ||| JJ
dia-gnosis  ||| S:408 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
these  ||| S:422 E:428 ||| DT
changes  ||| S:428 E:436 ||| NNS
at  ||| S:436 E:439 ||| IN
regular  ||| S:439 E:447 ||| JJ
gynecological  ||| S:447 E:461 ||| JJ
examinations  ||| S:461 E:474 ||| NNS
and  ||| S:474 E:478 ||| CC
adequate  ||| S:478 E:487 ||| JJ
treatment  ||| S:487 E:497 ||| NN
can  ||| S:497 E:501 ||| MD
prevent  ||| S:501 E:509 ||| VB
of  ||| S:509 E:512 ||| IN
malignant  ||| S:512 E:522 ||| JJ
transformation ||| S:522 E:536 ||| NN
.  ||| S:536 E:538 ||| .
Organized  ||| S:538 E:548 ||| JJ
cervical  ||| S:548 E:557 ||| JJ
screening  ||| S:557 E:567 ||| NN
and  ||| S:567 E:571 ||| CC
implementation  ||| S:571 E:586 ||| NN
of  ||| S:586 E:589 ||| IN
nationwide  ||| S:589 E:600 ||| JJ
vaccination  ||| S:600 E:612 ||| NN
against  ||| S:612 E:620 ||| IN
human  ||| S:620 E:626 ||| JJ
papillomavirus  ||| S:626 E:641 ||| NN
promises  ||| S:641 E:650 ||| VBZ
to  ||| S:650 E:653 ||| TO
reduce  ||| S:653 E:660 ||| VB
the  ||| S:660 E:664 ||| DT
incidence  ||| S:664 E:674 ||| NN
of  ||| S:674 E:677 ||| IN
cervical  ||| S:677 E:686 ||| JJ
cancer ||| S:686 E:692 ||| NN
.  ||| S:692 E:694 ||| .
